Overview

Administration of Kisspeptin in Patients With Hyperprolactinemia

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The goal of this project is to explore the use of exogenous pulsatile kisspeptin as a therapeutic alternative for patients with hyperprolactinemia who are intolerant to current therapies. Funding Source - FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Hormones